Literature DB >> 10789822

Dobutamine stress echocardiography: safety in diagnosing coronary artery disease.

F Lattanzi1, E Picano, E Adamo, A Varga.   

Abstract

Dobutamine stress echocardiography is considered a relatively well-tolerated diagnostic modality, effective in the management of patients with known or suspected coronary artery disease. Adverse effects during testing are relatively frequent, precluding the achievement of a diagnostic end-point in about 5 to 10% of tests. These adverse effects, mostly tachyarrhythmias and arterial hypotension, are usually minor and self limiting. However, severe life-threatening complications, as well as death, also occur. By analysing Medline-quoted literature up to March 1999, we found 35 original studies from a single institution with more than 100 patients, as well as 2 multicentre studies, concerning the feasibility and safety of dobutamine stress echocardiography. In a cumulative total of 26438 tests performed, 79 life-threatening complications (such as acute myocardial infarction, asystole, ventricular fibrillation, sustained ventricular tachycardia or severe symptomatic hypotension) have been reported, giving an incidence of 1 severe adverse reaction per every 335 examinations. In addition, 29 isolated case reports have been published describing life-threatening complications during dobutamine echocardiography. In case reports, 2 deaths have been described, both due to acute cardiac rupture in patients with recent inferior myocardial infarction. Severe adverse reactions during dobutamine echocardiography can be ischaemia independent, and are independent of operator experience and are unpredictable; some complications can be late occurring and long lasting. As a consequence, the procedure must be clearly indicated, written informed consent has to be obtained from the patient, an attending physician must be present during testing, and long term observation of outpatients is useful in order to manage late complications. In conclusion, while the safety of dobutamine stress echocardiography was reported to be outstanding in early reports, further experience presents a substantially more worrying picture. This must be taken into account by both physicians and patients when assessing the risk-benefit profile of the procedure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10789822     DOI: 10.2165/00002018-200022040-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  74 in total

1.  Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting.

Authors:  L H Ling; P A Pellikka; D W Mahoney; J K Oh; R B McCully; V L Roger; J B Seward
Journal:  J Am Coll Cardiol       Date:  1996-09       Impact factor: 24.094

2.  ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography.

Authors:  M D Cheitlin; J S Alpert; W F Armstrong; G P Aurigemma; G A Beller; F Z Bierman; T W Davidson; J L Davis; P S Douglas; L D Gillam; R P Lewis; A S Pearlman; J T Philbrick; P M Shah; R G Williams; J L Ritchie; K A Eagle; T J Gardner; A Garson; R J Gibbons; R A O'Rourke; T J Ryan
Journal:  J Am Coll Cardiol       Date:  1997-03-15       Impact factor: 24.094

3.  Assessment of coronary artery disease by dobutamine stress echocardiography (DSE).

Authors:  R K Chan; A M Tonkin; S Byrgiotis; P Calafiore
Journal:  Aust N Z J Med       Date:  1995-12

4.  Safety and feasibility of dobutamine-atropine stress echocardiography in patients with ischemic left ventricular dysfunction.

Authors:  J H Cornel; A H Balk; E Boersma; A P Maat; A Elhendy; M Arnese; A Salustri; J R Roelandt; P M Fioretti
Journal:  J Am Soc Echocardiogr       Date:  1996 Jan-Feb       Impact factor: 5.251

5.  RITED (Registro Italiano Test Eco-Dobutamina): side effects and complications of echo-dobutamine stress test in 3041 examinations.

Authors:  A Pezzano; F Gentile; A Mantero; A Morabito; P Ravizza
Journal:  G Ital Cardiol       Date:  1998-02

6.  Predicting the extent and location of coronary artery disease in acute myocardial infarction by echocardiography during dobutamine infusion.

Authors:  C Berthe; L A Pierard; M Hiernaux; G Trotteur; P Lempereur; J Carlier; H E Kulbertus
Journal:  Am J Cardiol       Date:  1986-12-01       Impact factor: 2.778

7.  Dobutamine-induced transmural myocardial ischemia in a patient with mild coronary lesions.

Authors:  F G Kardaras; M S Bonou; D F Kardara; A I Kranidis; E P Sioras; L P Anthopoulos
Journal:  Clin Cardiol       Date:  1996-02       Impact factor: 2.882

8.  Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test.

Authors:  A Elhendy; R T van Domburg; D Poldermans; J J Bax; P R Nierop; M L Geleijnse; J R Roelandt
Journal:  Diabetes Care       Date:  1998-11       Impact factor: 19.112

9.  [Adverse effects of dobutamine stress echocardiography].

Authors:  M Cladellas Capdevila; J Bruguera Cortada; J Hernández Herrero; J Villena Segura; R Serrat Serradell
Journal:  Rev Esp Cardiol       Date:  1996-01       Impact factor: 4.753

10.  Stress echocardiography: comparison of exercise, dipyridamole and dobutamine in detecting and predicting the extent of coronary artery disease.

Authors:  A Dagianti; M Penco; L Agati; S Sciomer; A Dagianti; S Rosanio; F Fedele
Journal:  J Am Coll Cardiol       Date:  1995-07       Impact factor: 24.094

View more
  11 in total

1.  BSE procedure guidelines for the clinical application of stress echocardiography, recommendations for performance and interpretation of stress echocardiography: a report of the British Society of Echocardiography Policy Committee.

Authors:  H Becher; J Chambers; K Fox; R Jones; G J Leech; N Masani; M Monaghan; R More; P Nihoyannopoulos; H Rimington; R Senior; G Warton
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

Review 2.  Cardiovascular magnetic resonance: structure, function, perfusion, and viability.

Authors:  David C Isbell; Christopher M Kramer
Journal:  J Nucl Cardiol       Date:  2005 May-Jun       Impact factor: 5.952

Review 3.  Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies.

Authors:  Vasken Dilsizian; Henry Gewirtz; Nicholas Paivanas; Anastasia N Kitsiou; Fadi G Hage; Nathan E Crone; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2015-05-15       Impact factor: 5.952

4.  [Cardiovascular magnetic resonance imaging: importance in coronary artery disease].

Authors:  M Neizel-Wittke; M Kelm
Journal:  Internist (Berl)       Date:  2014-01       Impact factor: 0.743

5.  Dobutamine-induced chest pain does not predict ischemic findings on myocardial perfusion imaging.

Authors:  John H Lee; Mohammad Abuannadi; Philip G Jones; Timothy Bateman; Randall Thompson; James H O'Keefe
Journal:  J Nucl Cardiol       Date:  2008-04-16       Impact factor: 5.952

6.  Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-10-01

7.  Complications during pharmacological stress echocardiography: a video-case series.

Authors:  Albert Varga; Giuliano Kraft; Ferenc Lakatos; Riccardo Bigi; Rafael Paya; Eugenio Picano
Journal:  Cardiovasc Ultrasound       Date:  2005-09-02       Impact factor: 2.062

8.  Ergonovine Stress Echocardiography for the Diagnosis of Vasospastic Angina and Its Prognostic Implications in 3,094 Consecutive Patients.

Authors:  Yeo Jeong Song; Sang Jin Ha; Dong Seok Lee; Woo Dae Bang; Dong Geum Shin; Yeongmin Woo; Sangsig Cheong; Sang Yong Yoo
Journal:  Korean Circ J       Date:  2018-10       Impact factor: 3.243

9.  STEMI after Dobutamine Stress Echocardiography in Hyperthyroid State.

Authors:  Mahmood Mubasher; Ashfaq Patel; Mohamed Magdi; Tahir Hamid
Journal:  Case Rep Cardiol       Date:  2019-04-02

10.  The assessment of coronary artery disease in patients with end-stage renal disease.

Authors:  Federica E Poli; Gaurav S Gulsin; Gerry P McCann; James O Burton; Matthew P Graham-Brown
Journal:  Clin Kidney J       Date:  2019-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.